The Cost-Effectiveness of Bendamustine-Rituximab (Ben-R) Versus R-Chop for the First Line Treatment of Patients with Indolent Non-Hodgkin’s Lymphoma (Inhl) in Colombia
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.247
https://www.valueinhealthjournal.com/article/S1098-3015(15)02323-2/fulltext
Title :
The Cost-Effectiveness of Bendamustine-Rituximab (Ben-R) Versus R-Chop for the First Line Treatment of Patients with Indolent Non-Hodgkin’s Lymphoma (Inhl) in Colombia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)02323-2&doi=10.1016/j.jval.2015.09.247
First page :
A818
Section Title :
Research Podium Presentations - Session 1
Open access? :
No
Section Order :
2470